Tissium Secures Up to $68M for Nerve Repair Platform Commercialization
Tissium secured up to €30 million (about $34.1 million) from the European Investment Bank, in addition to a prior financing round completed at the end of 2025, totaling approximately $68.2 million. The funding will support commercial rollout and clinical development for its sutureless nerve repair platform following FDA de novo authorization.
Topics: Biotech Investment MedTech Nerve Repair